ILD Journal Club

True/False: In the RECITAL trial, rituximab was not superior to cyclophosphamide in patients with CTD-ILD.

In a progressive pulmonary fibrosis trial, nerandomilast had a significant decline in FVC compared to placebo?

Which drug is NOT FDA approved for Pulmonary Fibrosis?

Which is the best indication to start antifibrotic therapy?

MOA of Nerandomilast is:

The primary endpoint in ILD treatment trials is usually:

The mortality rates in the RECITAL & Nerandomilast trial were?

In these trials, ILD patients stayed on their background immunosuppressives or antifibrotics?

Should glucocorticoids be used in ILD trials?

Which drug is being developed to treat pulmonary fibrosis?

Please select...

×